Get started
Author

Chris Garratt

Observed names: C Garratt, C J Garratt, C. Garratt, C. J. Garratt, C.J. Garratt, Chris J Garratt, Chris J. Garratt, Garratt C
ORCID: 0000-0002-2137-1017
Observed ORCID: 0000-0002-2137-1017
OpenAlex ID: A5063718926
Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
2013 · Milton Packer, Wilson Colucci, et al. · JACC Heart Failure · 446
PDF
Effects of dexmedetomidine and propofol on patient-ventilator interaction in difficult-to-wean, mechanically ventilated patients: a prospective, open-label, randomised, multicentre study
2016 · Giorgio Conti, Vito Marco Ranieri, et al. · Critical Care · 97
PDF
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients
2011 · Timo Iirola, Riku Aantaa, et al. · Critical Care · 96
PDF
Sibutramine pharmacokinetics in young and elderly healthy subjects
1999 · I. D. Hind, J. E. Mangham, et al. · European Journal of Clinical Pharmacology · 59
Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients
2013 · Pyry Antti Välitalo, Tuula Ahtola-Sätilä, et al. · Clinical Drug Investigation · 49
PDF
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
2003 · Milton Packer, Wilson S. Colucci, et al. · Journal of Cardiac Failure · 43
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
2023 · Karim Fizazi, Alice Bernard-Tessier, et al. · NEJM Evidence · 42
PDF
Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers
2000 · K. A. Wesnes, C. Garratt, et al. · British Journal of Clinical Pharmacology · 41
PDF
Management of hypertension in general practice: agreements with and variations from the British Hypertension Society guidelines.
1995 · J E Dickerson, C J Garratt, et al. · PubMed · 28
Prevalence and Spectrum of AR Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate Cancer
2024 · Emmanuel S. Antonarakis, Nicole Zhang, et al. · JCO Precision Oncology · 26
PDF
A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor®) in clinical practice in the EU
2017 · Mary Weatherall, Riku Aantaa, et al. · British Journal of Clinical Pharmacology · 23
PDF
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
2021 · Merit Cudkowicz, Angela Genge, et al. · The Lancet Neurology · 21
Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study
2004 · S Johansson, M Apajasalo, et al. · Critical Care · 11
PDF
Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.
2023 · Emmanuel S. Antonarakis, Nicole Zhang, et al. · Journal of Clinical Oncology · 10
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
2022 · Karim Fizazi, Natalie Cook, et al. · Journal of Clinical Oncology · 9
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
2004 · C Garratt, M Packer, et al. · Critical Care · 9
PDF
Influence of antipsychotic profile on cost of treatment of schizophrenia: A decision analysis approach
1998 · Bill D Byrom, Chris J Garratt, et al. · International Journal of Psychiatry in Clinical Practice · 9
MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.
2024 · Karim Fizazi, Guilhem Roubaud, et al. · Journal of Clinical Oncology · 8
Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
2020 · Petri Bono, Christophe Massard, et al. · ESMO Open · 8
PDF
Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC).
2022 · Alice Bernard-Tessier, Tapio Utriainen, et al. · Journal of Clinical Oncology · 6
Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials
2025 · Bill Byrom, Anthony Everhart, et al. · JMIR Cancer · 5
PDF
1605P Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
2024 · K. Fizazi, G. Roubaud, et al. · Annals of Oncology · 5
PDF
Phase I/II study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
2018 · P. Bono, C. Massard, et al. · Annals of Oncology · 4
1663TiP CYP11A1 inhibitor opevesostat (MK-5684) alone or in combination with other therapies for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): The phase I/II MK-5684-01A substudy
2024 · A. Hussain, C. Garratt, et al. · Annals of Oncology · 3
ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.
2024 · Alice Bernard-Tessier, Iben Spanggaard, et al. · Journal of Clinical Oncology · 3
PDF
Works count: 53
Citation count: 1,083
H-index: 12
I10-index: 14
Year
Topic
Type